TABLE 1.
Subject | Age (yr) | Race | Prior therapya | HIV-1 riskb | CD4+ T cell count (cells/mm3) | HIV-1 RNA in plasma (copies/ml) |
---|---|---|---|---|---|---|
1 | 37 | Caucasian | Yes | M | 169 | 74,335 |
3 | 43 | Black | No | M | 464 | 149,049 |
4 | 33 | Hispanic | Yes | M, I | 163 | 18,742 |
5 | 24 | Caucasian | Yes | M, I | 282 | 35,331 |
10 | 32 | Caucasian | No | M, I | 342 | 29,144 |
11 | 44 | Caucasian | No | M | 591 | 166,875 |
13 | 38 | Caucasian | No | M, I | 107 | 46,390 |
17 | 40 | Caucasian | No | M | 571 | 1,673 |
20 | 50 | Caucasian | No | I | 215 | 4,380 |
23 | 32 | Caucasian | No | M | 726 | 10,022 |
25 | 35 | Caucasian | No | M | 553 | 23,145 |
26 | 35 | Hispanic | Yes | M | 473 | 538 |
Subjects with a prior history of antiretroviral therapy, which in all instances was limited to nucleoside analog reverse transcriptase inhibitor treatment.
M, men having sex with men; I, intravenous drug use.